Promising cancer treatment modality: the University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program

Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non- toxic. Whenthe tumor is then exposed to neutrons, a relatively non-toxic form of radiation, crytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not contain the NCA. The UC Davis NCT program is currently working to develop and test new compounds or NCA in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable to treating clinical brain tumor patients by NCT and only two US facilities, MIT and Brookhaven National Laboratory. In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.

[1]  L. K. Norris,et al.  Adjuvant and neoadjuvant treatment for primary brain tumors in adults. , 1995, Seminars in oncology.

[2]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[3]  W. Sauerwein Principles and history of neutron capture therapy. , 1993, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[4]  A. Soloway,et al.  Boron neutron capture therapy for cancer. Realities and prospects , 1992 .

[5]  R. Barth,et al.  Boron neutron capture therapy of cancer. , 1990, Cancer research.

[6]  R. Barth,et al.  Boron neutron capture therapy for cancer. , 1990, Scientific American.

[7]  N. de Manzini,et al.  [Realities and prospects of viscero-synthesis]. , 1990, Il Giornale di chirurgia.

[8]  D. Gabel,et al.  Clinical phase-I study of Na2B12H11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). , 1994, International journal of radiation oncology, biology, physics.

[9]  L. Salford,et al.  Ten-year survival among patients with supratentorial astrocytomas grade III and IV. , 1988, Journal of neurosurgery.

[10]  R. Dorn Boron neutron capture therapy (BNCT): a radiation oncology perspective. , 1994, International journal of radiation oncology, biology, physics.

[11]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[12]  J. Gibson,et al.  A review of boron neutron capture therapy (BNCT) and the design and dosimetry of a high-intensity, 24 keV, neutron beam for BNCT research. , 1988, The British journal of radiology.